Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial-Reference-Cited by-同舟云学术

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial

Published:2018-11 Issue:11 Volume:19 Page:1504-1515
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Roach Mack,Moughan Jennifer,Lawton Colleen A F,Dicker Adam P,Zeitzer Kenneth L,Gore Elizabeth M,Kwok Young,Seider Michael J,Hsu I-Chow,Hartford Alan C,Horwitz Eric M,Yamoah Kosj,Jones Christopher U,Michalski Jeff M,Lee W Robert,Pisansky Thomas M,Rabinovitch Rachel,Rotman Marvin,Pryzant Rodger M,Kim Harold E,Thomas Charles R,Shipley William U,Sandler Howard M

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610;Roach;J Clin Oncol,2008

2. Radiotherapy and short-term androgen deprivation for localized prostate cancer;Jones;N Engl J Med,2011

3. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system;Zietman;Int J Radiat Oncol Biol Phys,1997

4. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions;Morikawa;Int J Radiat Oncol Biol Phys,2011

5. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79–20;Rotman;JAMA,1995

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials;Clinical and Translational Radiation Oncology;2024-11

2. Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-10

3. Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study;Clinical and Translational Radiation Oncology;2024-09

4. Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec–led Phase 3 Trial;European Urology;2024-09

5. The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO);Strahlentherapie und Onkologie;2024-08-28